Literature DB >> 24395800

Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.

Vivian Wai Yan Lui1, Noah D Peyser, Patrick Kwok-Shing Ng, Jozef Hritz, Yan Zeng, Yiling Lu, Hua Li, Lin Wang, Breean R Gilbert, Ignacio J General, Ivet Bahar, Zhenlin Ju, Zhenghe Wang, Kelsey P Pendleton, Xiao Xiao, Yu Du, John K Vries, Peter S Hammerman, Levi A Garraway, Gordon B Mills, Daniel E Johnson, Jennifer R Grandis.   

Abstract

The underpinnings of STAT3 hyperphosphorylation resulting in enhanced signaling and cancer progression are incompletely understood. Loss-of-function mutations of enzymes that dephosphorylate STAT3, such as receptor protein tyrosine phosphatases, which are encoded by the PTPR gene family, represent a plausible mechanism of STAT3 hyperactivation. We analyzed whole exome sequencing (n = 374) and reverse-phase protein array data (n = 212) from head and neck squamous cell carcinomas (HNSCCs). PTPR mutations are most common and are associated with significantly increased phospho-STAT3 expression in HNSCC tumors. Expression of receptor-like protein tyrosine phosphatase T (PTPRT) mutant proteins induces STAT3 phosphorylation and cell survival, consistent with a "driver" phenotype. Computational modeling reveals functional consequences of PTPRT mutations on phospho-tyrosine-substrate interactions. A high mutation rate (30%) of PTPRs was found in HNSCC and 14 other solid tumors, suggesting that PTPR alterations, in particular PTPRT mutations, may define a subset of patients where STAT3 pathway inhibitors hold particular promise as effective therapeutic agents.

Entities:  

Keywords:  STAT3 activation; driver mutations; phosphatase mutations

Mesh:

Substances:

Year:  2014        PMID: 24395800      PMCID: PMC3903220          DOI: 10.1073/pnas.1319551111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

Review 1.  Tumour suppressor function of protein tyrosine phosphatase receptor-T.

Authors:  Anthony Scott; Zhenghe Wang
Journal:  Biosci Rep       Date:  2011-10       Impact factor: 3.840

2.  Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

Authors:  Leopold Groesser; Eva Herschberger; Arno Ruetten; Claudia Ruivenkamp; Enrico Lopriore; Markus Zutt; Thomas Langmann; Sebastian Singer; Laura Klingseisen; Wulf Schneider-Brachert; Agusti Toll; Francisco X Real; Michael Landthaler; Christian Hafner
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

3.  Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.

Authors:  David A Solomon; Jung-Sik Kim; Julia C Cronin; Zita Sibenaller; Timothy Ryken; Steven A Rosenberg; Habtom Ressom; Walter Jean; Darell Bigner; Hai Yan; Yardena Samuels; Todd Waldman
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

4.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

Authors:  Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

5.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

6.  Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers.

Authors:  Claudia A L Ruivenkamp; Tom van Wezel; Carlo Zanon; Alphons P M Stassen; Cestmir Vlcek; Tamás Csikós; Anita M Klous; Nikos Tripodis; Anastassis Perrakis; Lucie Boerrigter; Peter C Groot; Jan Lindeman; Wolter J Mooi; Gerrit A Meijjer; Gert Scholten; Hans Dauwerse; Vaclav Paces; Nico van Zandwijk; Gert Jan B van Ommen; Peter Demant
Journal:  Nat Genet       Date:  2002-06-24       Impact factor: 38.330

7.  Mutational analysis of the tyrosine phosphatome in colorectal cancers.

Authors:  Zhenghe Wang; Dong Shen; D Williams Parsons; Alberto Bardelli; Jason Sager; Steve Szabo; Janine Ptak; Natalie Silliman; Brock A Peters; Michiel S van der Heijden; Giovanni Parmigiani; Hai Yan; Tian-Li Wang; Greg Riggins; Steven M Powell; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-05-21       Impact factor: 47.728

Review 8.  Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.

Authors:  Brian W Dymock; Cheng Shang See
Journal:  Expert Opin Ther Pat       Date:  2013-02-01       Impact factor: 6.674

9.  Tumor-derived extracellular mutations of PTPRT /PTPrho are defective in cell adhesion.

Authors:  Jianshi Yu; Scott Becka; Peng Zhang; Xiaodong Zhang; Susann M Brady-Kalnay; Zhenghe Wang
Journal:  Mol Cancer Res       Date:  2008-07       Impact factor: 5.852

10.  Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability.

Authors:  Sebastian Korff; Stefan M Woerner; Yan P Yuan; Peer Bork; Magnus von Knebel Doeberitz; Johannes Gebert
Journal:  BMC Cancer       Date:  2008-11-10       Impact factor: 4.430

View more
  43 in total

Review 1.  [Immunomodulation as innovative therapy for head and neck tumors : Current developments].

Authors:  P J Schuler; J C Doescher; S Laban; T K Hoffmann
Journal:  HNO       Date:  2016-07       Impact factor: 1.284

Review 2.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

3.  Knockdown of protein tyrosine phosphatase receptor U inhibits growth and motility of gastric cancer cells.

Authors:  Yongjie Liu; Zhichuan Zhu; Zhiqi Xiong; Jing Zheng; Zelan Hu; Jiangfeng Qiu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

4.  Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining.

Authors:  Junior Tayou
Journal:  Cell Oncol (Dordr)       Date:  2018-04-20       Impact factor: 6.730

5.  Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.

Authors:  Nelson Ung; Tracy L Putoczki; Stanley S Stylli; Irvin Ng; John M Mariadason; Timothy A Chan; Hong-Jian Zhu; Rodney B Luwor
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

6.  Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.

Authors:  Matthew L Hedberg; Gerald Goh; Simion I Chiosea; Julie E Bauman; Maria L Freilino; Yan Zeng; Lin Wang; Brenda B Diergaarde; William E Gooding; Vivian W Y Lui; Roy S Herbst; Richard P Lifton; Jennifer R Grandis
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

7.  JNK1/2 expression and modulation of STAT3 signaling in oral cancer.

Authors:  Ioannis Gkouveris; Nikolaos Nikitakis; Maria Karanikou; George Rassidakis; Alexandra Sklavounou
Journal:  Oncol Lett       Date:  2016-05-24       Impact factor: 2.967

Review 8.  The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.

Authors:  Jessica L Geiger; Jennifer R Grandis; Julie E Bauman
Journal:  Oral Oncol       Date:  2015-12-28       Impact factor: 5.337

9.  Characterization of functionally active gene fusions in human papillomavirus related oropharyngeal squamous cell carcinoma.

Authors:  Theresa Guo; Daria A Gaykalova; Michael Considine; Sarah Wheelan; Aparna Pallavajjala; Justin A Bishop; William H Westra; Trey Ideker; Wayne M Koch; Zubair Khan; Elana J Fertig; Joseph A Califano
Journal:  Int J Cancer       Date:  2016-03-30       Impact factor: 7.396

10.  STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.

Authors:  Noah D Peyser; Lin Wang; Yan Zeng; Marie Acquafondata; Maria Freilino; Hua Li; Malabika Sen; William E Gooding; Masanobu Satake; Zhenghe Wang; Daniel E Johnson; Jennifer R Grandis
Journal:  Cancer Prev Res (Phila)       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.